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Background: Door-to-balloon times strongly correlate with survival in patients referred
for primary PCI. Guidelines have recommended that regions develop STEMI systems that
quickly triage patients for primary PCI. We sought to evaluate door-to-balloon time
amongst patients referred for primary PCI according to different referral pathways in the
province of Ontario.
Methods: We used the provincial primary PCI registry database developed by the
Cardiac Care Network of Ontario Cath/PCI Working Group. We identified all patients
who underwent primary PCI between July 2009 and December 2011 at 14 PCI capable
centers. We evaluated time to reperfusion according to the following referral pathways: i)
Field directly to the PCI center catheterization laboratory; ii) Field to the PCI center
emergency department (ED); iii) Field to a non-PCI center ED; iv) Self-transport (Self-T)
to a PCI capable center ED; v) Self-T to a non-PCI capable center ED. We excluded
in-hospital patients presenting with STEMI on the wards. The primary endpoint was the
first hospital door-to-balloon-time.
Results: 6198 patients were referred for primary PCI. PCI was performed in 5678
patients. Data was available to calculate door-to-balloon times in 4763 patients. Amongst
these patients, 63% were transported initially from the field, and 37% self-transported to
the ED. The median door-to-balloon time with interquartile range for each referral
pathway is shown in the table. Patients referred directly to the cath lab had significantly
faster door-to-balloon times.
Door-to-balloon time (minutes)
Time
Field to PCI
center cath
lab
Field to PCI
center ED
Field to
non-PCI
center
Self-T to
PCI
center
ED
Self-T to
non-PCI
center
ED
P value>N1310 N717 N 970 N510 N1256
Median 46 80 122 104 120 0.0001
IQR 34-63 58-111 95-184 77-146 97-171
Conclusions: Prehospital triage is associated with very short door-to-balloon times when
patients are transported directly to the catheterization laboratory. Self-transport leads to
shorter door-to-balloon time when the pt presents at a PCI center. These results are
relevant to regions planning to develop STEMI systems.
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Background: The effect of multi-vessel disease (MVD) with or without a concomitant
coronary chronic total occlusion (CTO) has never been investigated in patients treated
with rescue percutaneous coronary intervention (PCI). This study evaluates whether there
is an increased rate of death at 1-year follow-up in patients undergoing rescue PCI with
angiographic pattern of MVD and a concurrent CTO in comparison with single vessel
disease (SVD) and MVD without CTO.
Methods: Among 551 consecutive patients undergoing rescue PCI, we compared the
1-year survival rates of 361 patients with SVD, 137 with MVD without a CTO and 53
with MVD and a CTO.
Results: Patients with MVD were older than SVD (62	10 vs 57	11 yrs, p0.001) and
more often admitted with cardiogenic shock (14% vs 3% p0.001). Patients with MVD
and CTO had more often previous myocardial infarction (19% vs 4% vs 4%, p0.001),
lower ejection fraction (42	11% vs 47	11% vs 49	11%) and longer pain to PCI time
(8	6 vs 7	5 vs 7	5 hours, p0.001) compared with patients with SVD and MVD
without CTO, respectively. The 1-year mortality rates of patients with SVD, MVD
without CTO and MVD with CTO were 5%, 13% and 27% respectively (P0.001). The
Cox proportional hazard model identified the presence of MVD with CTO as a strong
predictor of death at 1-year follow-up (HR: 3.4, 95% CI: 1.6 to 7.1, p0.001) while MVD
alone did not result as a predictor of outcome (HR: 1.9, 95% CI: 0.9 to 3.8, p0.064).
Adjusted 1-year overall survival rates were 96%, 91.4% and 83.4%, (p0.001) in the
groups with SVD, MVD without and with CTO, respectively.
Conclusions: Patients with MVD and concurrent CTO have higher mortality rates than
those with SVD or MVD without CTO at 1-year follow-up after rescue PCI. MVD with
CTO and not MVD alone is a predictor of death at 1-year follow up.
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Background: Rates of stent thrombosis (ST) may vary overtime and the relationship of
this complication with non-adherence to dual antiplatelet therapy (DAPT) during
long-term follow-up remains unclear.
Methods: We analyzed 2,997 patients who were treated with at least 1 stent and in whom
a non-target vessel ST did not occur during follow-up from the large-scale HORIZONS-
AMI trial of patients with STEMI undergoing primary PCI. Aspirin was prescribed
indefinitely, and a theinopyridine for at least 6 months. DAPT usage was evaluated
according to the development of ST in 4 time periods (1 month, 1-6 months, 6-12
months and 1 year from index stent implantation).
Results: Rates of ST and DAPT usage are shown in the Table. DAPT non-usage was
lowest within the first month, and we observed no relationship between confirmed
discontinuation of antiplatet therapy and stent thrombosis during the first month. During
the 1-6 month period we observed a clear relationship between non-usage of DAPT and
definite/probable ST. However, this relationship was absent in the 6-12 month period.
Beyond one year, ST was associated with non-usage of aspirin but was paradoxically
more common in patients taking a thienopyridine.
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Patients with
Definite or
Probable
Stent
Thrombosis
No Stent
Thrombosis P value
vents Under 30 Days: n74 n2923
Confirmed Discontinuation
of Thienopyridine
2/65 (3.08%) 54/2794 (1.93%) 0.37
Confirmed Discontinuation
of Aspirin
3/65 (4.62%) 59/2789 (2.12%) 0.17
Confirmed Discontinuation
of Thienopyridine or
Aspirin
5/65 (7.69%) 106/2795 (3.79%) 0.11
Confirmed Discontinuation
on Both Aspirin and
Thienopyridine
0/60 (0%) 7/2696 (0.26%) 1
Events From 30 Days to
6 months:
n15 n2908
Confirmed Discontinuation
of Thienopyridine
5/13 (38.5%) 204/2704 (7.54%) 0.002
Confirmed Discontinuation
of Aspirin
5/13 (38.5%) 65/2701 (2.41%) 0.0001
Confirmed Discontinuation
of Thienopyridine or
Aspirin
7/13 (53.8%) 250/2704 (9.25%) 0.0001
Confirmed Discontinuation
on Both Aspirin and
Thienopyridine
3/9 (33.3%) 19/2473 (0.77%) 0.0001
Events From 6 to 12
months:
n13 n2895
Confirmed Discontinuation
of Thienopyridine
6/12 (50.0%) 767/2661 (28.8%) 0.18
Confirmed Discontinuation
of Aspirin
0/11 (0%) 75/2660 (2.82%) 1
Confirmed Discontinuation
of Thienopyridine or
Aspirin
6/12 (50.0%) 803/2662 (30.2%) 0.20
Confirmed Discontinuation
on Both Aspirin and
Thienopyridine
0/6 (0%) 39/1898 (2.05%) 1
Events Beyond 1 year: n45 n2850
Confirmed Discontinuation
of Thienopyridine
11/36 (30.6%) 1662/2599 (63.9%) 0.0001
Confirmed Discontinuation
of Aspirin
5/37 (13.5%) 89/2594 (3.43%) 0.009
Confirmed Discontinuation
of Thienopyridine or
Aspirin
14/37 (37.8%) 1697/2599 (65.3%) 0.0008
Confirmed Discontinuation
on Both Aspirin and
Thienopyridine
2/25 (8.00%) 54/956 (5.65%) 0.65
Conclusions: In the HORIZONS-AMI trial of patents with STEMI undergoing stent
implantation, the relationship between ST and non-usage of DAPT was complex and
varied overtime. It was strong during the 1-6 month timeframe, but not between 6 and 12
months. Hereafter, very late ST was associated with non-usage of aspirin but not of a
thienopyridine.
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Background: In the medical literature several cases of Tako-tsubo cardiomyopathy
(TTC) with critical coronary artery disease (CAD) has been reported, and in the clinical
practice several typical TTC cases shown significant stenosis of coronary arteries that
cannot be related to the dysfunctional myocardium. The aim of this study is to evaluate
the prevalence, clinical characteristics and outcome of patients with TTC and critical CAD
in a large multicentre database.
Methods: In the 26 participating centers, 450 patients admitted with the diagnosis of TTC
(modified Mayo Criteria) underwent coronary angiography within 48 hours of hospital
admission and were progressively included in the Tako-tsubo Italian Network (TIN)
Registry.
Results: Overall, 43 (9.6%) patients had at least 1 critical coronary stenosis ( 50%) not
supplying the dysfunctional myocardium, or a previous myocardial revascularization
(percutaneous or surgical), while 407 (90.4%) had not critical stenosis or truly normal
coronary arteries. TTC patients with critical CAD were more likely to have advanced age,
diabetes, familiar history of CAD, acute functional mitral regurgitation and a delayed left
ventricular function recovery as compared with those without. At 6-month follow-up, the
incidence of death, TTC recurrence and rehospitalization rates were similar between
patients with critical CAD and patients with normal coronary arteries (Table). At
multivariable Cox analysis, independent predictors of death were Charlson comorbidity
index while the presence of CAD did not significantly influence mid-term outcome.
Variable
TTC Patients (n450)
p value
Critical CAD Not critical CAD
n43 (9.6%) n407 (90.4%)
Chest pain 1 (2%) 14 (4%) 0.693
Dyspnoea 4 (10%) 14 (4%) 0.067
TTC recurrence 0 (0%) 1 (0.3%) 0.739
Rehospitalization 5 (12%) 23 (6%) 0.152
Cardiac causes 3 (7%) 11 (3%) 0.146
Non cardiac causes 2 (5%) 12 (3%) 0.584
Death 2 (5%) 11 (3%) 0.504
Cardiac causes 1 (2%) 5 (1%) 0.579
Non cardiac causes 1 (2%) 6 (2%) 0.698
Conclusions: The presence of significant CAD is a possible finding in a not trivial
proportion of patients with TTC. Thus, when the the stenotic artery does not supply the
dysfunctional myocardium, the presence of angiographically significant CAD should not
be considered an exclusion criteria for TTC.
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Background: Primary percutaneous coronary intervention (PPCI) is currently the
treatment of choice for patients presenting with ST-segment elevation acute myocardial
infarction (STEMI). The purpose of the present study is to determine the incidence and
predictors of 30 days mortality in elderly patients with STEMI treated with PPCI.
Methods: Prospective observational study. Consecutive patients older than 75 years with
STEMI undergoing PPCI in our Hospital were enrolled between January 2006 to
December 2009. Prior PPCI, patients received loading dose of 300 mg Clopidogrel and
325-500 mg of Aspirin. Unfractionated Heparin was administered according to current
guidelines. Abxicimab was administered at physician’s discretion. Statistical analysis was
performedwith SPSS v.18.
Results: Among 1,619 STEMI patients admitted for PPCI, 369(22.8%) were older than
75 years. Mean age was 80.1 3.9 years, 196(53.1%) male patients, 90 (24.4%) diabetes
mellitus, 51 (13.8%) prior myocardial infarction, 11 (3%) prior congestive heart failure,
30 (8.3%) in Killip class III-IV, 315  238 minutes mean time of symptoms onset to
PPCI. 30 days all-cause mortality occurred in 58 (16.4%) patients and cardiac mortality
in 53 (15.1%). Univariate analysis determined age older than 81.3 years, non loading dose
of Aspirin and Clopidogrel prior PPCI, Killip class 3-4 presentation, final TIMI grade flow
less than 3 and prior congestive heart failure as predictors of 30 days mortality. A
multivariate logistic regression analysis was performed, identifying as independent
predictors of 30 days mortality Killip class 3-4 and final TIMI grade flow less than 3.
Conclusions: Among patients older than 75 years with STEMI undergoing PPCI in our
center, 30 days all-cause mortality was 16.4%, mainly due to cardiac causes(15.1%). Only
Killip class 3-4 and final TIMI grade flow less than 3 were identified as independent
predictors of 30 days mortality.
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